The Democratic Republic of Congo has recorded over 2,011 deaths from the ongoing Ebola epidemic, according to the latest official figures—a milestone that health authorities warn could make this the deadliest outbreak in the country’s history. Government data released overnight confirmed 4,381 confirmed cases across multiple provinces.

The trajectory is alarming: while the first 1,000 fatalities took nearly nine weeks to accumulate, the next 1,000 were recorded in just three weeks, signaling a rapid acceleration that has overwhelmed response efforts.

Logistical nightmares are to blame. Remote villages remain cut off due to armed conflict, impassable roads, and strikes by healthcare workers protesting unpaid wages. These obstacles have crippled the delivery of medical supplies, testing kits, and protective equipment, allowing the virus to spread unchecked.

Dr. Jean-Marie Akandabo, who oversees patient care at a clinic in Ituri, described the situation as “critical”. He urged immediate scaling up of interventions in affected areas to prevent further loss of life.

This marks the 17th Ebola outbreak in the DRC, already the largest in the country’s history. Sania Nishtar, CEO of Gavi, the Vaccine Alliance, cautioned that “this could become the most devastating outbreak ever recorded”. The current fatality rate stands at 45.9%, significantly higher than the 39.6% recorded during the 2014–2016 West Africa epidemic—the deadliest in global history, which claimed over 11,000 lives.

State of emergency declared

The outbreak was officially declared on May 15, but genetic sequencing reveals it likely began in February. Authorities have since declared a national health emergency. Unlike previous outbreaks, this one involves the rare Bundibugyo strain, for which no approved vaccines or treatments exist. Clinical trials for experimental vaccines have begun in Ituri Province, the epicenter of the crisis.

Vaccine trials offer a glimmer of hope

On Friday, WHO vaccine experts recommended launching large-scale human trials with Ervebo, the only Ebola vaccine currently licensed. While it targets the more common Zaire strain, preliminary animal data suggest it may provide partial protection against the Bundibugyo strain. Two other experimental vaccines are in early human trial phases, with a third in development.

WHO’s Africa Regional Director, Dr. Mohamed Yakub Janabi, admitted that “we’re chasing the virus, which is always one step ahead”. The agency warns that without effective vaccination, containment relies solely on isolating cases and treating patients in secure facilities until recovery or death. In regions plagued by conflict and broken communications, early detection—critical to halting transmission—becomes nearly impossible.

Ebola spreads through contact with bodily fluids and causes severe hemorrhagic fever. First identified in 1976 near the Ebola River in what is now the DRC, this virus has resurfaced repeatedly, each time testing the limits of public health systems in one of the world’s most fragile regions.